Technical Analysis for RCUS - Arcus Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Death Cross | Bearish | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 2.94% | |
| Oversold Stochastic | Weakness | 2.94% | |
| Slingshot Bearish | Bearish Swing Setup | 0.55% | |
| Oversold Stochastic | Weakness | 0.55% | |
| NR7 | Range Contraction | 1.31% | |
| Lower Bollinger Band Touch | Weakness | 1.31% |
| Alert | Time |
|---|---|
| Up 5% | about 17 hours ago |
| 60 Minute Opening Range Breakout | about 17 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
| Up 3% | about 17 hours ago |
| Up 2% | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/05/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.31 |
| 52 Week Low | 13.52 |
| Average Volume | 755,432 |
| 200-Day Moving Average | 16.38 |
| 50-Day Moving Average | 16.36 |
| 20-Day Moving Average | 15.79 |
| 10-Day Moving Average | 15.50 |
| Average True Range | 0.98 |
| RSI (14) | 40.48 |
| ADX | 12.17 |
| +DI | 23.68 |
| -DI | 26.56 |
| Chandelier Exit (Long, 3 ATRs) | 16.05 |
| Chandelier Exit (Short, 3 ATRs) | 17.08 |
| Upper Bollinger Bands | 17.79 |
| Lower Bollinger Band | 13.78 |
| Percent B (%b) | 0.23 |
| BandWidth | 25.37 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.35 |
| MACD Histogram | -0.2015 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.01 | ||||
| Resistance 3 (R3) | 15.98 | 15.53 | 15.79 | ||
| Resistance 2 (R2) | 15.53 | 15.19 | 15.54 | 15.71 | |
| Resistance 1 (R1) | 15.11 | 14.99 | 15.32 | 15.14 | 15.64 |
| Pivot Point | 14.66 | 14.66 | 14.76 | 14.67 | 14.66 |
| Support 1 (S1) | 14.24 | 14.32 | 14.45 | 14.27 | 13.76 |
| Support 2 (S2) | 13.79 | 14.12 | 13.80 | 13.69 | |
| Support 3 (S3) | 13.37 | 13.79 | 13.61 | ||
| Support 4 (S4) | 13.40 |
